Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for
AstraZeneca in the ethical pharmaceutical sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and assessment of
financial performance, with 1-6 year sales forecasts for key drugs. An
interactive forecasting and analysis tool provides continually updated
quantitative and qualitative information.
Reasons to Purchase
- Benchmark AstraZeneca' s performance against key rivals in the ethical
pharmaceutical sector
- Assess AstraZeneca' s efforts to expand into the biologics segment via M&A
activity, primarily the acquisition of MedImmune
- Analyze the maturation of AstraZeneca' s product portfolio, a trend that
places further emphasis on the recent R&D setbacks suffered by the comp
View Cart
